JP2018009012A5 - - Google Patents

Download PDF

Info

Publication number
JP2018009012A5
JP2018009012A5 JP2017157335A JP2017157335A JP2018009012A5 JP 2018009012 A5 JP2018009012 A5 JP 2018009012A5 JP 2017157335 A JP2017157335 A JP 2017157335A JP 2017157335 A JP2017157335 A JP 2017157335A JP 2018009012 A5 JP2018009012 A5 JP 2018009012A5
Authority
JP
Japan
Prior art keywords
group
alkyl
divalent
sulfonamide
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017157335A
Other languages
English (en)
Japanese (ja)
Other versions
JP6496786B2 (ja
JP2018009012A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018009012A publication Critical patent/JP2018009012A/ja
Publication of JP2018009012A5 publication Critical patent/JP2018009012A5/ja
Application granted granted Critical
Publication of JP6496786B2 publication Critical patent/JP6496786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017157335A 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用 Active JP6496786B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773773P 2013-03-06 2013-03-06
US61/773,773 2013-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015561536A Division JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019043934A Division JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Publications (3)

Publication Number Publication Date
JP2018009012A JP2018009012A (ja) 2018-01-18
JP2018009012A5 true JP2018009012A5 (enExample) 2019-01-31
JP6496786B2 JP6496786B2 (ja) 2019-04-03

Family

ID=50382628

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015561536A Active JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157334A Active JP6602351B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157335A Active JP6496786B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2019043934A Active JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015561536A Active JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157334A Active JP6602351B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019043934A Active JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Country Status (20)

Country Link
US (3) US9850264B2 (enExample)
EP (2) EP3795148B1 (enExample)
JP (4) JP6196327B2 (enExample)
KR (2) KR102227201B1 (enExample)
CN (2) CN110279684B (enExample)
AR (1) AR095034A1 (enExample)
AU (3) AU2014225992B2 (enExample)
BR (2) BR112015021371B1 (enExample)
CA (2) CA2898301C (enExample)
CL (3) CL2015002485A1 (enExample)
ES (2) ES3036990T3 (enExample)
IL (3) IL241012B (enExample)
MX (2) MX364916B (enExample)
MY (1) MY207109A (enExample)
PH (3) PH12020500285B1 (enExample)
RU (2) RU2663911C2 (enExample)
SG (2) SG10201801471RA (enExample)
TW (1) TWI616200B (enExample)
WO (1) WO2014138037A1 (enExample)
ZA (1) ZA201505134B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5982001B2 (ja) * 2011-10-26 2016-08-31 アラーガン、インコーポレイテッドAllergan,Incorporated ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
NZ700733A (en) * 2012-04-16 2016-07-29 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CA2898301C (en) 2013-03-06 2021-11-16 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
WO2014138046A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
WO2015009545A1 (en) * 2013-07-16 2015-01-22 Allergan, Inc. Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
TW201536289A (zh) 2013-07-18 2015-10-01 Actelion Pharmaceuticals Ltd 作為alx受體激動劑之經哌取代橋聯螺[2,4]庚烷衍生物
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
BR112016027133A8 (pt) 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
EP3271327A4 (en) * 2015-03-19 2018-11-21 University of Maryland, Baltimore Runx2 transcription factor inhibitors and uses thereof
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN109715602A (zh) * 2016-03-28 2019-05-03 阿勒根公司 苯基脲衍生物作为n-甲酰肽受体调节剂
EP3442950A1 (en) * 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
RU2768587C2 (ru) 2016-10-06 2022-03-24 Дайити Санкио Компани, Лимитед Производное мочевины
CN109134533B (zh) * 2017-06-27 2020-08-11 维眸生物科技(上海)有限公司 一种含磷化合物及其制备和应用
CN107814773B (zh) * 2017-11-13 2020-05-22 西安交通大学 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用
RU2712229C2 (ru) * 2018-05-17 2020-01-27 Закрытое акционерное общество "Институт экспериментальной фармакологии" Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
JP2022151437A (ja) * 2021-03-26 2022-10-07 均 石井 網膜炎治療薬。
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases
WO2025239980A1 (en) * 2024-05-13 2025-11-20 University Of Virginia Patent Foundation Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
JPS63232846A (ja) 1987-03-20 1988-09-28 Haruo Ogura 新規な固定相担体
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
WO2001014328A2 (en) * 1999-08-20 2001-03-01 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
EP1537075B1 (en) * 2002-09-05 2009-07-01 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
ATE447586T1 (de) * 2002-11-07 2009-11-15 Takeda Pharmaceutical Fprl1-liganden und deren verwendung
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20060130064A (ko) 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, fprl1의 용도
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20080008694A1 (en) * 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
AU2007357448B2 (en) * 2006-09-18 2012-09-06 Compugen Ltd Bioactive peptides and method of using same
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
KR20100101055A (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동 관련 질환의 치료 또는 예방용 약학적 조성물
CA2803920A1 (en) 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2819457A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2827005A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA2839735A1 (en) 2011-06-17 2012-12-20 Yong-xin LI D-serine for the treatment of visual system disorders
US8440684B2 (en) 2011-07-11 2013-05-14 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (FPRL-1) receptor modulators
JP5982001B2 (ja) * 2011-10-26 2016-08-31 アラーガン、インコーポレイテッドAllergan,Incorporated ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
EP2814815A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
NZ700733A (en) 2012-04-16 2016-07-29 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CA2898301C (en) 2013-03-06 2021-11-16 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

Similar Documents

Publication Publication Date Title
JP2018009012A5 (enExample)
JP2017214416A5 (enExample)
JP2017214417A5 (enExample)
JP2017214418A5 (enExample)
JP2017066164A5 (enExample)
JP2011190260A5 (enExample)
JP2015063518A5 (ja) 有機化合物
JP2011207878A5 (enExample)
JP2011213717A5 (enExample)
BR112015005331B8 (pt) Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo
JP2015527363A5 (enExample)
NZ734896A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
JP2013010731A5 (ja) 複素環化合物
EA200901167A1 (ru) Бициклические органические соединения, пригодные для лечения воспалительных и аллергических состояний
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
DK2279187T3 (da) Spirocykliske derivater som histondeacetylaseinhibitorer
AR103199A1 (es) N-alquilaril-5-oxiaril-octahidrociclopenta[c]pirrol moduladores alóstericos negativos de nr2b
BR112015032689A2 (pt) composto heterocíclico fundido e uso em controle de pragas do mesmo
DOP2007000014A (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
EA201100368A1 (ru) Амидные соединения, полезные в терапии
JP2016529235A5 (enExample)
RU2014107744A (ru) Амидиновое соединение или его соль
JP2019500319A5 (enExample)